Skip to content
value.today

Avalyn Pharma Inc.: financial analysis

Ratios worked out from 2 fiscal years of Avalyn Pharma Inc.'s statements, compared with 671 companies in Biotechnology.

Avalyn Pharma Inc. scorecard#

Passes 2 of the 3 checks that could be worked out. Fiscal year 2025; market cap of Oct 28, 2026.

  • Valuation0 of 1
    • –P/E below its peers' medianNo P/E on file.
    • ✗Price to book below its peers' medianNo price to bookShareholders' equity is negative.
    • –Price to sales below its peers' medianNo Price to sales on file.
    • –Free cash flow yield above 5%No free cash flow yield on file.
    • –Earnings yield above the 10-year Treasury yieldNo P/E on file.
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growthnot known
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • –Earnings per share grew in the newest yearEarnings per share of two years are not on file.
    • –Net income higher than five years earlierNet income of five years earlier is not on file.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitabilitynot known
    • –Profitable in the newest yearNo net income on file.
    • –Profitable in each of the last five yearsFive years of net income are not on file.
    • –Operating margin above its peers' medianNo operating margin on file.
    • –Return on equity above 15%No return on equity (equity missing or negative).
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health2 of 2
    • ✓Short-term assets cover short-term liabilities10.2×Current ratio 10.19 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • ✓Net debt below three years of EBITDANet cashMore cash than debt: net cash of $52 M at the end of fiscal 2025.
    • –Operating income covers interest five timesInterest expense is not on file.
    • –Cash from operations positive in each of the last three yearsThree years of operating cash flow are not on file.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returnsnot known
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • –Share count up no more than 2% in a yearShare counts of two years are not on file.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 20, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

What the 2025 statements show#

Each line is an observation with its numbers, not a judgement of the company.

Strengths

  • More cash than debt: net cash of $52 million.

Worth a look

  • Shareholders' equity is negative: -$239 million.

Financial strength#

Avalyn Pharma Inc.: financial strength by fiscal year
Fiscal yearTrend20252024Median of peersAhead of
Net debt$-52 M—$-16 M66%
Current ratio10.19×—4.40×78%
Equity share of assets-160.3%—64.1%6%

How each figure is worked out#

Net debt
Total debt less cash. Negative means more cash than debt.
Current ratio
Assets due within a year divided by liabilities due within a year.
Equity share of assets
Shareholders' equity as a share of total assets.